News

Among people with ANCA-associated vasculitis (AAV) and interstitial lung disease (ILD), severe lung scarring and poorer lung function at the time of ILD diagnosis are tied to a higher risk of lung disease progression, respiratory failure, and death, a European study shows. ILD is a condition marked by inflammation and progressive…

In people with ANCA-associated vasculitis (AAV), infections were associated with higher odds of relapse and cardiovascular events, as well as a higher risk of death over time, according to a study in France. Data also showed that testing positive for self-reactive antibodies against the proteinase 3 (PR3) protein was…

Lung damage in people with ANCA-associated vasculitis (AAV) can vary widely depending on the type of self-reactive antibodies driving the disease. That’s according to the findings of a new study of AAV patients in Japan that used images from cast high-resolution CT scans, known as HRCTs. Specifically, the data…

InflaRx plans to launch a Phase 2 clinical trial to evaluate its experimental oral treatment, izicopan, in people with ANCA-associated vasculitis (AAV). The company believes izicopan has the potential to be a safer, faster, and more convenient alternative to Tavneos (avacopan), an oral therapy with a similar…

May is Vasculitis Awareness Month, and advocates are gearing up to raise awareness, foster connection within the community, and raise funds to fuel research into ANCA-associated vasculitis (AAV) and other disorders that are marked by blood vessel inflammation. This year’s awareness month coincides with the 40th anniversary of…

Children with ANCA-associated vasculitis (AAV) often have more active inflammation of the kidneys, as well as more severe signs of kidney disease, than do adults with AAV, according to a new study from France and Italy. Still, with monitoring and treatment, the long-term outcomes for pediatric patients are similar…

Following allegations of manipulated data in its regulatory application, a division of the U.S. Food and Drug Administration (FDA) has proposed withdrawing Tavneos (avacopan), an oral treatment approved for the most common forms of ANCA-associated vasculitis (AAV), from the market. In a press announcement, the FDA’s Center…

Blood levels of transferrin (Tf), a protein that transports iron in the body, may serve as a useful biomarker for tracking the activity, treatment response, and outcomes of ANCA-associated vasculitis (AAV). That’s according to a new study by researchers in China that found that individuals with active AAV had…

Updated criteria for classifying ANCA-associated vasculitis (AAV) in adults better discriminate between the AAV types granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children than the current pediatric classification criteria. That’s according to a study comparing classification results of 574 children between the…

Treatment with Nkarta’s lead candidate NKX019 in two ongoing, early-phase clinical trials may soon be available in outpatient settings — potentially expanding access for people with ANCA-associated vasculitis (AAV) and other autoimmune disorders — thanks to a new regulatory nod. The company announced it has reached an agreement…